샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737290

신장병 치료제 시장

Nephrology Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신장병 치료제 세계 시장은 2030년까지 219억 달러에 달할 전망

2024년에 167억 달러로 추정되는 신장병 치료제 세계 시장은 2024년부터 2030년까지 CAGR 4.6%로 성장하여 2030년에는 219억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 경구 투여는 CAGR 4.0%를 기록하며 분석 기간 종료시에는 127억 달러에 달할 것으로 예측됩니다. 비경구 투여 부문의 성장률은 분석 기간 동안 CAGR 5.3%로 추정됩니다.

미국 시장은 45억 달러로 추정, 중국은 CAGR 7.2%로 성장 예측

미국의 신장병 치료제 시장은 2024년에 45억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 43억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.2%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.3%와 4.6%로 예측됩니다. 유럽에서는 독일이 CAGR 2.9%로 성장할 것으로 예측됩니다.

세계의 신장병 치료제 시장 - 주요 동향과 촉진요인 정리

신장병 치료제가 전 세계적으로 증가하는 신장 관련 질환의 부담을 관리하는 데 중요한 이유는 무엇일까?

만성콩팥병(CKD), 급성신장병(AKI), 사구체신염, 신증후군, 말기신장병(ESRD) 등 신장 기능에 영향을 미치는 질환을 대상으로 하는 신장병 치료제는 전 세계적으로 증가하는 신장 관련 건강 부담에 대응하기 위해 주목받고 있습니다. 국제신장학회에 따르면 전 세계적으로 8억 5,000만 명 이상이 신장 질환을 앓고 있으며, 약리학적 개입은 질병의 진행을 늦추고 합병증을 최소화하며 환자의 삶의 질을 향상시키는 데 핵심적인 역할을 하고 있습니다.

그 주요 요인으로는 당뇨병, 고혈압, 비만, 고령화 등의 급격한 증가를 들 수 있으며, 이 모든 것이 신장의 위험을 크게 증가시킵니다. 또한, 신장 합병증은 발견이 늦어지는 경우가 많아 기능을 안정시키고 투석이나 이식을 예방하기 위해 적극적인 약물 치료가 필요합니다. 그 치료법은 항고혈압제(ACE 억제제, ARB), 적혈구 조혈촉진제(ESA), 인산결합제, 칼륨결합제, 나트륨-포도당 공수송체2(SGLT2) 억제제, 면역억제제 등 다양합니다. 신장학은 일차 진료와 전문 의료가 교차하는 분야이기 때문에 이 분야의 약물 혁신은 심장 대사 및 면역학 영역으로 확장되고 있습니다.

치료 혁신과 신장 특화 약물 설계가 질병 관리를 어떻게 변화시키고 있는가?

SGLT2 억제제는 초기에는 제2형 당뇨병 치료제로 승인되었으나, 신장을 보호하고, CKD의 진행을 지연시키며, 신기능이 저하된 환자의 심부전으로 인한 입원율을 감소시키는 등 신장 질환에 특화된 약물 혁신이 그 원동력이 되고 있습니다. 으로 인한 입원율을 감소시켰습니다. 비스테로이드성 미네랄 코르티코이드 수용체 길항제(MRA)인 파인레논은 당뇨병성 신질환에서 알부민뇨를 감소시키고 ESRD를 지연시키는 것으로 입증된 또 다른 획기적인 치료제입니다.

생물학적 제제 및 표적 면역억제제는 루푸스 신염, 국소분절성 사구체 경화증(FSGS), IgA 신증과 같은 사구체 질환에 대해서도 개발되고 있습니다. 베림맙, 보크로스포린과 같은 단클론항체는 자가면역성 신질환의 치료 옵션을 넓히고 있습니다. 정밀 투여 알고리즘, 신장 약리유전체학, 신장 청소율 감소에 맞춘 약물전달 시스템은 CKD의 단계에 관계없이 보다 안전하고 효과적인 치료를 가능하게 하고 있습니다. 이러한 발전으로 신장학은 소극적 치료에서 적극적 장기 보존 치료로 전환되고 있습니다.

어떤 환자 집단과 지역 의료 시스템이 신장내과 치료제에 대한 수요를 형성하고 있는가?

당뇨병, 고혈압, 노화로 인한 신장 기능 저하로 인해 신장병 치료제가 필요한 가장 큰 환자군은 당뇨병, 고혈압, 노화로 인한 신장 기능 저하이며, CKD는 특히 미국, 남아시아, 아프리카 일부 지역에서 검진 및 조기 개입에 대한 접근성이 제한된 노인과 유색인종에게 불균형적으로 영향을 미치고 있습니다. 전 세계 투석 인구는 향후 10년간 500만 명을 넘어설 것으로 예상되며, 빈혈 치료제, 인산염 조절제, 칼륨 안정화제에 대한 지속적인 수요를 견인하고 있습니다.

북미는 높은 투석 인구, 성숙한 투석 인프라, 전문 의료진에 대한 접근성 등을 바탕으로 시장을 선도하고 있습니다. 유럽은 통합 신장 치료 경로와 SGLT2 억제제의 보급으로 인해 근소한 차이로 그 뒤를 잇고 있습니다. 아시아태평양은 당뇨병성 신증의 높은 유병률, 미진단 인구의 증가, 상환 제도의 발전으로 인해 가장 빠르게 성장하고 있습니다. 인도, 중국, 일본에서는 질병 유병률의 증가와 현지 제약사들의 신장 치료제에 대한 투자가 모두 증가하고 있습니다. 라틴아메리카와 중동은 신흥 시장으로 도시화와 비감염성 질환의 확산으로 인해 신장병 치료제의 보급이 가속화되고 있습니다.

신장병 치료제 시장의 장기적인 성장과 혁신의 원동력은?

신장병 치료제 시장의 성장 원동력은 세계 인구의 고령화, 당뇨병 및 심혈관질환과 같은 합병증 증가, 투석 및 이식에 대한 의존도를 예방해야 하는 임상적 시급성입니다. 전 세계 의료 정책은 CKD 스크리닝, 바이오마커에 의한 계층화, 조기 약리학적 개입을 강조하고 있으며, 1차 의료에서 3차 의료까지 신장병 치료제의 역할을 강화하고 있습니다. 신장 전문의, 내분비 전문의, 순환기 전문의의 공동 진료 모델은 통합 처방을 더욱 촉진하고 있습니다.

섬유증, 염증, 내피 기능 장애를 표적으로 하는 신약으로 인해 파이프라인의 기술 혁신이 가속화되고 있습니다. 제약사와 신장 연구 네트워크와의 제휴를 통해 신속한 임상시험, 실제 데이터 분석, 바이오마커 검증이 가능해졌고, eGFR 모니터링 앱, AI 기반 신질환 위험도 계산기와 같은 디지털 헬스 툴은 맞춤형 치료와 복약 순응도를 지원하고 있습니다. CKD가 전 세계 건강 이슈의 상위권에 위치한 가운데, 신장병 치료제는 신장 보호뿐만 아니라 심장-신장-대사 축에 걸친 전신적 혜택을 제공하는 필수적인 존재로 남을 것으로 보입니다.

부문

투여 경로(경구, 비경구, 기타 투여 경로), 약물 종류(ACE 억제제, 안지오텐신 수용체 길항제, B 차단제, 칼슘 길항제, 루프 이뇨제, 적혈구 조혈자극인자 제제, 인산 결합제, 기타 약물 종류), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 41개사)

  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Biocon Limited
  • CSL Vifor
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc(GSK)
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Nephrology Drugs Market to Reach US$21.9 Billion by 2030

The global market for Nephrology Drugs estimated at US$16.7 Billion in the year 2024, is expected to reach US$21.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$12.7 Billion by the end of the analysis period. Growth in the Parenteral Administration segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 7.2% CAGR

The Nephrology Drugs market in the U.S. is estimated at US$4.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Nephrology Drugs Market - Key Trends & Drivers Summarized

Why Are Nephrology Drugs Critical in Managing the Rising Global Burden of Kidney-Related Disorders?

Nephrology drugs, which target conditions affecting renal function-including chronic kidney disease (CKD), acute kidney injury (AKI), glomerulonephritis, nephrotic syndrome, and end-stage renal disease (ESRD)-are gaining prominence in response to the growing global prevalence of kidney-related health burdens. With over 850 million people worldwide affected by kidney diseases, according to the International Society of Nephrology, pharmacological intervention has become central to delaying disease progression, minimizing complications, and improving patient quality of life.

Key drivers include the rapid rise in diabetes, hypertension, obesity, and aging populations-all of which significantly elevate renal risk. Moreover, kidney complications are often detected late, necessitating aggressive pharmacological management to stabilize function and prevent dialysis or transplantation. Therapies span a wide range, including antihypertensives (ACE inhibitors, ARBs), erythropoiesis-stimulating agents (ESAs), phosphate binders, potassium binders, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and immunosuppressants. With nephrology intersecting both primary care and specialty medicine, drug innovation in this space is expanding into cardiometabolic and immunological domains.

How Are Therapeutic Innovations and Renal-Specific Drug Designs Transforming Disease Management?

The therapeutic landscape for nephrology is shifting from symptom management to disease-modifying approaches, driven by drug innovations that specifically target renal pathology. SGLT2 inhibitors, initially approved for type 2 diabetes, have demonstrated renal protective effects, slowing progression of CKD and reducing hospitalization rates for heart failure in patients with impaired renal function. Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), is another breakthrough therapy shown to reduce albuminuria and delay ESRD in diabetic kidney disease.

Biologics and targeted immunosuppressants are also being developed for glomerular diseases such as lupus nephritis, focal segmental glomerulosclerosis (FSGS), and IgA nephropathy. Monoclonal antibodies like belimumab and voclosporin are expanding treatment options in autoimmune nephropathies. Precision dosing algorithms, renal pharmacogenomics, and drug delivery systems tailored for reduced renal clearance are enabling safer and more effective therapy across CKD stages. These developments are shifting nephrology from reactive treatment to proactive, organ-preserving care.

Which Patient Populations and Regional Healthcare Systems Are Shaping Demand for Nephrology Therapeutics?

The largest patient cohorts requiring nephrology drugs are those with diabetes, hypertension, and aging-related renal function decline. CKD disproportionately affects older adults and people of color, particularly in the U.S., South Asia, and parts of Africa where access to screening and early intervention remains limited. The global dialysis population-projected to surpass 5 million in the next decade-also drives ongoing demand for anemia management, phosphate regulation, and potassium stabilization drugs.

North America is the leading market, driven by high disease prevalence, mature dialysis infrastructure, and widespread access to specialist care. Europe follows closely with integrated renal care pathways and widespread adoption of SGLT2 inhibitors. Asia-Pacific is experiencing the fastest growth due to high rates of diabetic nephropathy, large undiagnosed populations, and evolving reimbursement frameworks. India, China, and Japan are witnessing both rising disease incidence and local pharmaceutical investment in renal therapeutics. Latin America and the Middle East are emerging markets, where urbanization and non-communicable disease prevalence are accelerating nephrology drug uptake.

What Is Fueling Long-Term Growth and Innovation in the Nephrology Drugs Market?

The growth in the nephrology drugs market is fueled by an aging global population, increasing incidence of comorbidities such as diabetes and cardiovascular disease, and the clinical urgency of preventing dialysis and transplant dependence. Global health policy is emphasizing CKD screening, biomarker-driven stratification, and early pharmacological intervention, reinforcing the role of nephrology drugs across primary and tertiary care. Collaborative care models between nephrologists, endocrinologists, and cardiologists are further boosting integrated prescribing.

Pipeline innovation is accelerating with novel agents targeting fibrosis, inflammation, and endothelial dysfunction. Partnerships between pharma firms and renal research networks are enabling rapid clinical trials, real-world data analysis, and biomarker validation. Digital health tools, including eGFR monitoring apps and AI-driven nephropathy risk calculators, are supporting personalized therapy and medication adherence. As CKD moves up the global health agenda, nephrology drugs will remain indispensable-delivering not only renal protection but systemic benefits across the heart-kidney-metabolic axis.

SCOPE OF STUDY:

The report analyzes the Nephrology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Parenteral, Other Administration Routes); Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents, Phosphate Binders, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Biocon Limited
  • CSL Vifor
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Nephrology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Kidney Disease Spurs Demand for Nephrology Therapeutics
    • Expansion of Geriatric Population Globally Strengthens Business Case for Long-Term Nephrology Care
    • Increase in Diabetic and Hypertensive Patient Populations Drives Growth in Renal Drug Prescriptions
    • Launch of Next-Generation SGLT2 Inhibitors Throws the Spotlight on Renoprotective Drug Classes
    • Introduction of Non-Steroidal Mineralocorticoid Receptor Antagonists Expands Therapeutic Options
    • Regulatory Approvals of First-In-Class Therapies Accelerate Adoption of Innovative Renal Treatments
    • Surge in Dialysis-Associated Complications Generates Demand for Adjunct Nephrology Therapies
    • Expansion of CKD Clinical Management Guidelines Propels Adoption of Early-Stage Interventions
    • Growing Emphasis on Cardiovascular-Renal Drug Synergies Enhances Combination Therapy Utilization
    • Adoption of AI-Driven Risk Stratification Tools Supports Personalized Nephrology Drug Regimens
    • Increasing Access to Nephrology Services in Emerging Markets Expands Addressable Patient Base
    • Heightened Focus on Patient Adherence and Quality-of-Life Outcomes Drives Long-Acting Formulations
    • Rising Investments in Rare Kidney Disorder Research Spurs Orphan Drug Development
    • Integration of Biomarkers in Kidney Function Monitoring Enhances Drug Efficacy Targeting
    • Growth in Renal Transplant Cases Strengthens Demand for Post-Operative Nephrology Drugs
    • Challenges in Reimbursement and Therapy Affordability Create Market Access Barriers
    • Improved Diagnostic Screening Rates for Early Kidney Disease Spur Preventive Treatment Adoption
    • Availability of Biosimilars for Renal Anemia Management Expands Cost-Effective Treatment Access
    • Digital Patient Monitoring in CKD Care Pathways Supports Therapy Optimization
    • Global Harmonization of Renal Drug Trial Protocols Facilitates Multinational R&D
    • Expansion of Home Dialysis Trends Reinforces Need for Supportive Nephrology Pharmacotherapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nephrology Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nephrology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Angiotensin Receptor Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Angiotensin Receptor Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Loop Diuretics Erythropoiesis-Stimulating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Phosphate Binders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • JAPAN
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • CHINA
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • EUROPE
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Nephrology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • FRANCE
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • GERMANY
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Nephrology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • INDIA
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Nephrology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Nephrology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Nephrology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
  • AFRICA
    • Nephrology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Nephrology Drugs by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Nephrology Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Nephrology Drugs by Drug Class - Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Nephrology Drugs by Drug Class - Percentage Breakdown of Value Sales for Other Drug Classes, ACE Inhibitors, Angiotensin Receptor Blockers, B-Blockers, Calcium Channel Blockers, Loop Diuretics Erythropoiesis-Stimulating Agents and Phosphate Binders for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Nephrology Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Nephrology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제